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Down-regulation of Fca receptors on blood cells of IgA nephropathy
patients: Evidence for a negative regulatory role of serum IgA. IgA
nephropathy (IgAN) is associated with increased serum IgA1 and IgA1-
immune complexes (IC). As Fca receptors (FcaR) are candidate mole-
cules to regulate IgA levels, increased receptor occupation by IgA1
prompted us to study the expression of FcaR on blood cells of IgAN
patients. Surface and cytoplasmic FcaR expression were markedly de-
creased on monocytes, despite normal levels of transcripts. FcaR expres-
sion on patients’ neutrophils was slightly decreased, exclusively at the cell
surface. However, when autologous plasma was removed from the cells
FcaR was up-regulated. This observation led us to search for circulating
regulatory factors. In vitro experiments revealed that FcaR was down-
regulated on normal monocytes following long-term culture with control
or patient purified serum IgA at high concentrations (5 mg/ml). Moreover,
polymeric myeloma IgA1 induced stronger down-regulation than mono-
meric IgA1. These results point to a negative regulatory role of serum IgA
on surface FcaR expression. This is also supported by a negative corre-
lation between levels of FcaR on blood cells and serum IgA. On the other
hand, endogenous IgA bound to IgAN cells was significantly higher than
IgA bound to control cells pre-incubated with patients’ plasma, suggesting
abnormalities in the receptor-ligand interaction. Patient FcaR had a
higher Mr (60 to 85 kDa) than those of controls (55 to 75 kDa) and a
decreased binding to a sialic acid-specific lectin on blots, indicating
post-translational modifications with impaired sialylation of surface FcaR
molecules that might be involved in enhanced IgA binding. Continuous
FcaR occupation by IgA, associated with receptor down-regulation, might
contribute to the enhancement of circulating IgA1 and IgA1-IC by
impairing their binding and degradation. Finally, increased receptor
occupation by IgA on monocytes was linked to mesangial proliferation and
glomerular sclerosis, suggesting a role for IgA-bound cells in the patho-
genesis of mesangial damage.
IgA nephropathy (IgAN) is the most common form of glomer-
ulonephritis (GN) and is characterized by granular deposits of
IgA1 in the mesangium [1, 2]. Although the clinical features of
IgAN have been known for almost two decades [3, 4], the
pathogenic mechanisms are only just emerging. Abnormalities in
IgA itself were initially indicated by physicochemical studies
revealing that mesangial and circulating IgA were mainly poly-
meric and anionic [5–9], despite the fact that the serum monomer/
polymer IgA ratio remains within the normal range [10]. A
glycosylation defect of serum IgA1 has been shown by decreased
binding to a lectin, jacalin [11], and by a decrease in galactose
residues on serum IgA1 molecules [12–15]. Galactose deficient
IgA1 represents a small population of IgA1 molecules that forms
complexes with IgG [15]. In vivo studies in mice have shown that
undergalactosylated human IgA1 binds preferentially to the kid-
neys rather than to the liver [13]. This binding seems to be
mediated through IgA receptors expressed on mesangial cells
[16].
Serum levels of IgA1 molecules and IgA1-containing immune
complexes (IgA1-IC) are increased in patients with IgAN [10, 17].
Overproduction of IgA1 and/or defective clearance could be
involved in augmented IgA1 levels. Increased synthesis of IgA1 by
B cells has been reported in IgAN [18], but delayed blood
clearance of IgA1-IC has also been reported, suggesting an
impaired catabolism by IgA receptors [19]. Two IgA receptors are
the main candidate receptors involved in IgA catabolism and
clearance of IgA1-IC from the circulation: (i) the asialoglycopro-
tein receptor (ASGP-R) expressed by hepatocytes, which binds
IgA via its O-linked moieties [20], and (ii) IgA Fc receptors
(FcaR; CD89) [21, 22], which are expressed on blood and tissue
myeloid cells as multiple isoforms named a.1, a.2 and a.3 that
differ by deletions in their extracellular domains [23]. ASGP-R
appears to function normally, according to in vivo studies using
asialo-a1-acid glycoprotein as ligand [19], but FcaR dysfunctions
have been observed, including higher occupation by endogenous
IgA associated with delayed kinetics of FcaR-mediated endocy-
tosis [24]. Altered expression and glycosylation of FcaR have been
found in other diseases associated with increased levels of serum
IgA, including human immunodeficiency virus infection (HIV)
and alcoholic liver cirrhosis (ALC) [25, 26].
Increased receptor occupation by IgA1 in IgAN patients [24]
led us to investigate the expression and biochemical properties of
FcaR molecules in their blood phagocytic cells. We found a
marked decrease in FcaR expression on blood phagocytic cells
that was linked to elevated levels of serum IgA, and an associa-
tion of FcaR occupation by IgA on monocytes with mesangial
damage in IgAN. In vitro experiments revealed a negative regu-
latory role of serum IgA levels in receptor expression on blood
monocytes.
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METHODS
Subjects
Heparinized blood was obtained from 43 patients with biopsy-
proven IgA nephropathy (32 males and 11 females) and 39
healthy subjects (22 males and 17 females). Ten patients with
other types of GN were also studied (5 with membranous glomer-
ulonephritis and 5 with minimal change disease). Forty-two
patients were selected on the basis of no moderate or severe renal
failure, and no steroid treatment. One patient with moderate
renal failure without treatment (patient A.R.) was studied. None
had clinical or biochemical evidence of liver disease, Henoch-
Scho¨nlein syndrome or HIV infection. Total serum IgA levels
(mg/ml) determined by nephelometry were 4.4 6 0.2 in patients
with IgA nephropathy (N 5 31) and 1.95 6 0.2 in healthy
individuals (N 5 25). This study was approved by the Ethics
Committee of Necker Hospital.
Antibodies
The following monoclonal antibodies (mAbs) were used: A59
(IgG1k), A62 (IgG1k), A77 (IgG1k) specific for FcaR [27]; IV.3
(IgG2b) (ATCC) specific for FcgRII; 3G8 (IgG1k) (ATCC)
specific for FcgRIII; anti-IgA (IgG1k; CH-EB6-8) [28]; anti-IgA1
(IgG3l; 1-155-1) and anti-IgA2 (IgG2bk; 14-3-26) [29]; IgG1k
(clone TPO 6.12 kindly provided by Professor J.F. Kearney,
University of Alabama, Birmingham, AL, USA) and an IgG2b
used as negative control; anti-CD3 and anti-CD19 (Becton Dick-
inson, Mountain View, CA, USA); phycoerythrin-labeled anti-
FcaR A59 (A59-PE) was either prepared by Dr. C. Zuber
(Immunotech, Marseille, France) or purchased from PharMingen
(San Diego, CA, USA); FITC-conjugated goat antibody specific
for mouse Ig (Southern Biotechnology Associates; Birmingham,
AL, USA); PE-coupled anti-CD11b (IgG1k; Caltag Laboratories,
San Francisco, CA, USA); FITC-coupled anti-CD13 (IgG1k
Immunotech); PE-coupled anti-CD14 (IgG1k; Becton Dickin-
son); PE labeled IgG1 (Becton Dickinson) used as negative
control; FITC-conjugated F(ab9)2 fragments of goat anti-human
IgA and FITC-coupled anti-FcgRII (IV.3-FITC) prepared in our
laboratory; FITC-labeled goat anti-mouse Ig antibodies, PE-
coupled F(ab9)2 fragments of goat anti-human IgA and PE-
labeled streptavidin were purchased from Southern Biotechnol-
ogy Associates Inc. Human IgG was prepared from normal serum.
Human myeloma IgA and FITC- or biotin-conjugated F(ab9)2
fragments of goat anti-idiotype (Id) were prepared as previously
described [30]. Polymeric and monomeric IgA1k was purified by
gel chromatography [30]. IgA from six IgAN patients (S.L., S.I.,
J.A., J.C., I.M. and L.R.) and six normal individuals were purified
from 20 ml of sera by ammonium sulfate precipitation and affinity
purification on a Sepharose 4B column coupled to anti-IgA mAb
(IgG1k; CH-EB6-8) [27], concentrated to 10 mg/ml using a
Centricon apparatus (Amicon, Beverly, MA, USA) and filtered
through a 0.2 mm filter. The purity of IgA (. 95%) was evaluated
by SDS-PAGE and Western blot with anti-IgA Ab. The percent-
age of polymers in total IgA (estimated by scan analysis) were
18 6 3.5% (ranging from 23 to 15%) for IgAN patients and 15 6
3% for normal individuals.
Cell culture with IgA
The human monocytic cell line U937 was cultured in RPMI
1640 medium (Life Technologies Inc., Gaithesburg, MD, USA)
supplemented with 10% fetal calf serum (FCS), 2 mM glutamine,
100 IU ml21 penicillin, 100 mg ml21 streptomycin and 20 mg/ml
polymyxin B, with or without various concentrations of purified
IgA (dialyzed against RPMI). Mononuclear cells (MNC) were
isolated from whole blood of normal individuals by Ficoll-
Hypaque (Pharmacia Biotech, Uppsala, Sweden) gradient centrif-
ugation and submitted to plastic adherence for two hours at 37°C
with 7% CO2 in 24-well plates at 5 3 10
6 cells/ml in RPMI 5%
FCS. After removing non-adherent cells, 5 mg/ml IgA from each
tested individual was added to wells in the presence of RPMI-10%
FCS containing polymyxin B, as described above. Adherent cells
were removed by trypsin-EDTA treatment (Gibco BRL, Balti-
more, MD, USA) since FcaR is resistant to this treatment [21].
Immunofluorescence analysis
Endogenous IgA bound to cell surface receptors was detected
using FITC- or PE-labeled F(ab9)2 fragments of anti-IgA antibod-
ies as previously described [24–26]. FITC- or biotin-labeled
F(ab9)2 fragments of anti-Id antibodies were used as negative
controls. In some experiments, blood cells were incubated with
patients’ plasma at 4°C for one hour, washed twice in PBS
containing 5% FCS and 0.1% NaN3, and stained with 10 ml of
PE-labeled F(ab9)2 fragments of anti-IgA antibodies. Cells were
also stained with an anti-IgA mAb (CH-EB6-8), an anti-IgA1
mAb (1-155-1] or an anti-IgA2 mAb (14-3-26) plus FITC-labeled
goat anti-mouse antibodies as previously described [26]. Myeloma
IgA binding was analyzed using biotin-labeled F(ab9)2 fragments
of goat anti-Id antibodies and PE-labeled streptavidin as devel-
oping reagents [26]. Surface FcaR expression was analyzed using
A59-PE [25]. IgG1-PE mAb and FITC-coupled IV.3 anti-FcgRII
antibody (10 ml at 0.1 mg/ml) were used as negative and positive
controls, respectively. In some experiments, indirect immunoflu-
orescence (IF) assay was performed using A59 mAb plus FITC-
conjugated anti-mouse Ig antibodies as described previously [24].
In all experiments, red blood cells were lysed after staining (lysis
buffer, Becton Dickinson), and then cells were washed and
analyzed by flow cytometry (FACScan analyzer; Becton Dickin-
son). The neutrophil and monocyte populations were discrimi-
nated from other blood cells by using forward and side light-
scatter characteristics as described elsewhere [24]. Staining with
myeloid markers, including anti-CD11b, anti-CD13, and anti-
CD14 was used for control gates for neutrophils and monocytes
before acquisition on the FACScan. Antibody reactivities were
expressed as their fluorescence intensities (FI) obtained in the
peak channel. To analyze cytoplasmic expression of FcaR, puri-
fied neutrophils and mononuclear cells (MNC) were cytospun
(5 3 104 cells per slide), fixed and permeabilized for 20 minutes at
220°C with 95% ethanol and 5% acetic acid. After washes in PBS,
cells were incubated for 20 minutes with 30 ml of mouse mAb
(0.05 mg/ml) and with FITC-labeled goat anti-mouse Ig antibody
(0.05 mg/ml) as developing reagent, as described elsewhere [27].
Biochemical analysis of FcaR
Mononuclear cells and granulocytes were isolated by centrifu-
gation over density gradients using neutrophil isolation medium
as previously described [25, 26]. Monocytes (. 88% pure) were
obtained by immunodepletion of T and B lymphocytes and
natural killer cells [26]. The purity of both cell types was evaluated
by Giemsa staining. Cells (107) were surface-labeled with Na125I
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(1 mCi; Amersham International, Amersham, UK) by the lac-
toperoxidase method, lysed in 2 ml of 0.5% NP40 lysis buffer
containing protease inhibitors; lysates were preadsorbed by hu-
man IgG coupled to beads three times, and FcaR molecules were
immunoprecipitated as previously described [25–27]. Materials
were resolved by sodium dodecylsulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) [31]. Molecular weight markers were
bought from Bio-Rad Laboratories.
Western blot analysis of FcaR using carbohydrate-specific
lectins
Freshly isolated neutrophils (2 3 107) were lysed in 2 ml of
0.5% NP40 lysis buffer containing protease inhibitors [27]. Lysates
were adsorbed using Sepharose 4B-beads coupled to human IgG,
IgG1k antibody (TPO-6-12) and anti-FcgRII mAb (IV.3) to
eliminate FcgR. Adsorbed lysates were then incubated with either
irrelevant IgG1k control (TPO 6-12) or with A59 mAb (80 mg)
plus 40 mg of goat anti-mouse Ig-coupled beads for two hours at
4°C. Immunoprecipitates were migrated in Mini-SDS-10% PAGE
and proteins were electrotransferred from the gel to a nitrocellu-
lose (NC) sheet (Hybond RPN-203C; Amersham) for one hour at
80 V in transfer buffer containing 10 mM NaHCO3, 3 mM
Na2CO3; pH 9.9, 20% (vol/vol) methanol with a cooling system
maintaining temperature below 25°C, as described elsewhere [32].
Nitrocellulose sheets were blocked overnight at 4°C in 0.02 M Tris
buffer pH 7.4 containing 0.5 M NaCl, 0.1 mM CaCl2, 0.1 mM
MgCl2, 0.1 mM MnCl2 and 1% fish gelatin to avoid nonspecific
fixation. Nitrocellulose sheets were incubated with biotinylated
lectins according to the manufacturer’s instructions (Genzyme or
Oxford Glycosystem, Abingdon, UK) for one hour at room
temperature on a shaker. The two lectins used in this study were
Sambucus nigra agglutinin (SNA), which binds to terminal sialic
acid linked to galactose, and Concanavalin A (Con A), which
binds to carbohydrates with terminal mannose or glucose resi-
dues. After extensive washes, NC sheets were incubated for 30
minutes with horseradish peroxidase-labeled streptavidin at
1/5000 dilution (Amersham). After the washes, the filter was
developed using an enhanced chemiluminescence detection sys-
tem (ECL; Amersham).
Analysis of FcaR transcripts
RNA extraction, reverse transcription (RT) and polymerase
chain reaction (PCR) were performed as previously described
[23]. Briefly, total RNA was extracted by the acid-phenol proce-
dure from 5 3 106 cells [33] and cDNA synthesis was performed
using 2 mg of RNA. PCR was then performed by adding 2 ml of
cDNA, 20 pmol of sense primer from the 59 leader region and 20
pmol of antisense primer from the 39 noncoding region of FcaR
Fig. 1. Detection of IgA on the surface of blood
phagocytes in IgA nephropathy (IgAN). Blood
cells were first extensively washed at 4°C and
then stained with F(ab9)2 fragments of anti-IgA
Ab coupled to FITC. Cells were analyzed by
flow cytometry using either neutrophil or
monocyte forward/side scatter acquisition gates
as described in the Methods section. (A)
Representative FACS profiles of phagocytes
from a normal subject (Co) and an IgAN
patient. Overlayed left histograms represent
background fluorescence with anti-idiotype
antibody (negative control). (B) Fluorescence
intensity (FI) values from controls, IgAN and
other glomerulonephritis (GN) patients were
obtained in the peak channel of each FACS
profile. FI was calculated as follows: (x of anti-
IgA-stained cells 2 x of background control
staining), in which x indicates the computer
value for FI (peak channel) on each FACS
profile. Differences between controls and
patients were analyzed using Student’s t-test
and the Mann-Whitney U test. *P , 0.001;
**P , 0.02.
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cDNA (or an actin cDNA) using Taq DNA polymerase (Life
Technologies). The mix was subjected to 25 to 50 cycles of
denaturation at 94°C for 45 seconds, annealing at 62°C for 45
seconds, and extension at 75°C for one minute in a thermal cycler.
PCR products were separated on 1.2% agarose gels. For cloning
and sequencing PCR-amplified products were separated by elec-
trophoresis through 1.5% agarose, and the band corresponding to
a1 product [23] was excised and purified using a silica matrix
based Qiaex II kit (Qiagen Inc., Hilden, Germany). Restriction
sites in 59 of each primer were used to clone PCR products by
ligating in pBluescript vector (pBS KS1; Stratagene) using the T4
DNA ligase (Life Technologies). Ligated vectors were used to
transform competent Escherichia coli. For sequencing, cloned
PCR products were denatured in 0.2 M NaOH for 20 minutes at
65°C and annealed with 0.5 pmol of FcaR primers (#1, ATG
GAC CCC AAA CAG ACC ACC; #2, CAG GAA GGG GAC
TTC CCC ATG; #3, GAC GCA AAC AAG GCA GGG CGC;
#4, GGG GAA CAC CCG GCC AAC TTC; #5, TTC AAC CAG
TAT GGC CAA GAG; #6, GGG GGA TCC TCC TCT CTG
CCT TCA CC, 59 to 39, respectively). The DNA were then
synthesized using dideoxynucleotides, 33P-ddNTP and recombi-
nant DNA polymerase (Thermo Sequenase kit; Amersham),
followed by separation on 6% denaturing polyacrylamide gel
electrophoresis and autoradiography.
Statistical analysis
We used Student’s independent sample two-tailed test, the
non-parametric Mann-Whitney U test and Yates’ X2 test as
indicated. Correlation analysis was conducted by linear regression
analysis. Results are presented as means 6 SEM.
RESULTS
Increased occupation of IgA receptors by endogenous IgA1
In a previous study we observed increased levels of endogenous
IgA bound to the surface of blood phagocytic cells from IgAN
patients [24]. Here, we first extended this study to a larger number
of IgAN patients (N 5 20) by staining blood phagocytic cells with
F(ab9)2 fragments of anti-IgA antibodies. Significantly higher
levels of IgA were observed on the surface of monocytes and
neutrophils from patients [fluorescence intensity (FI), 2.9 6 0.1
and 1.9 6 0.07, respectively] than controls (FI, 1.1 6 0.04 and
1.1 6 0.06; P , 0.001 and P , 0.02, respectively; Fig. 1). Normal
levels of IgA were detected on cells from patients with minimal
change and membranous GN (“other GN”; Fig. 1B). We there-
fore determined the subclass of IgA occupying the FcaR by
staining blood cells with anti-IgA1 or anti-IgA2 mAb. IgA1 was
the predominant subclass on the surface of phagocytic cells from
patients with IgAN (Fig. 2A). Furthermore, the degree of recep-
Fig. 2. (A) IgA1 is the main subclass at the
surface of IgA nephropathy (IgAN) phagocytes.
Blood cells were washed and then stained with
anti-IgA1 monoclonal antibody (mAb), anti-
IgA2 mAb, or IgG2b mAb (control), plus
FITC-conjugated goat anti-mouse IgG
antibodies as developing reagent. Cells were
analyzed by FACS as described in Figure 1.
Specific mAb binding is indicated by arrows
(IgA1 or IgA2). The left histogram represents
staining with an irrelevant IgG1 mAb. (B)
Decreased IgA binding to phagocytes from an
IgAN patient. Blood cells were extensively
washed and incubated with polymeric myeloma
IgA1 for one hour on ice. After washes, cells
were incubated with biotin-labeled F(ab9)2
fragments of relevant goat anti-Id antibodies
and PE-labeled streptavidin, and analyzed by
FACS as described in the Methods section.
Five thousand cells were collected using FSC/
SSC gates. Specific IgA binding is indicated by
arrows. Background fluorescence of anti-Id
antibodies alone is shown on the left
histograms.
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tor occupancy was evaluated by binding of exogenous ligand,
purified polymeric IgA1 myeloma. As shown in Figure 2B, binding
of polymeric IgA to monocytes and neutrophils from an IgAN
patient was reduced, indicating receptor occupation and/or a
decrease in receptor numbers. This was consistently found in all
10 IgAN patients analyzed (monocyte FI, 14.9 6 0.9 and 30.7 6
1.8; neutrophil FI, 14.4 6 1.1 and 19 6 1.5 for IgAN patients and
controls (N 5 10; Mann Whitney U test, P , 0.02 and P , 0.05,
respectively). Intracellular content in IgA was also evaluated by IF
staining of permeabilized neutrophils and MNC of six IgAN
patients using an anti-IgA mAb (clone CH-EB6-8). Monocytes
were identified within MNC by double staining with an anti-CD14
mAb (not shown). Figure 3 shows the vesicular pattern of IgA
obtained from cytoplasmic staining of monocytes from two rep-
resentative IgAN patients, whereas no staining was seen in
monocytes from controls. No intracellular IgA was detected in
neutrophils from either patients or controls (data not shown).
To determine whether increased receptor occupation by IgA on
the cell surface merely reflected the increase in polymeric IgA [5],
which is known to bind FcaR better than monomeric IgA [30],
blood cells from healthy donors were incubated with patients’
plasma at 4°C for one hour, washed, and stained with F(ab9)2
fragments of anti-IgA antibodies. As shown in Table 1, incubation
with IgAN plasma significantly increased IgA binding to normal
blood cells. However, endogenous IgA bound to IgAN cells
remained significantly higher than IgA binding to plasma-treated
control cells, suggesting receptor alterations.
Decreased expression of FcaR on blood phagocytic cells
To minimize the effect of receptor clustering by secondary
antibodies [26], direct IF staining of whole blood cells was
performed ex vivo with an anti-FcaR mAb (A59) that recognizes
epitopes outside the IgA binding site [27]. Figure 4A shows
representative FACS profiles of neutrophils and monocytes from
a normal individual and an IgAN patient. Significant decreases in
mAb A59 reactivity were observed on monocytes and neutrophils
from patients with IgAN (FI, 34 6 1.5 for monocytes and 20 6 1.9
for neutrophils) as compared to controls (52 6 2.3 for monocytes
and 32 6 2.7 for neutrophils; Fig. 4B). In contrast, staining with
anti-FcgRII (CD32) (IV.3) was not different between the patient
and control monocytes (FI, 33 6 0.6, N 5 16 and 27 6 0.35, N 5
20, respectively) or neutrophils (FI, 24 6 0.8 and 25 6 0.4,
respectively). In addition, no changes in mAb A59 reactivity were
observed in patients with minimal-change disease or membranous
GN (Fig. 4B). FcaR levels correlated negatively with serum IgA
Fig. 3. Detection of intracytoplasmic IgA in
monocytes of IgA nephropathy (IgAN) patients.
Isolated mononuclear cells (MNC) were
cytospun, fixed and permeabilized in 95%
ethanol/5% acetic acid at 220°C and stained
with an irrelevant IgG1k (not shown) or anti-
IgA mAb (CH-EB6-8) plus FITC-coupled goat
anti-mouse Ig Ab as the developing reagent.
The arrows indicate the presence of cytoplasmic
staining on monocytes.
Table 1. Analysis of IgA bound to blood phagocytic cells, before and after preincubation with plasma from IgA nephropathy (IgAN) patients
Cell treatment with
IgAN plasma
(N 5 13)
Monocytes Neutrophils
FI
Controls (N 5 13) 2 23 6 2.4 22.6 6 1.2
NSb P , 0.01a
Controls (N 5 13) 1 29 6 3.4 31 6 2.0
P , 0.01a P , 0.01a
IgAN (N 5 13) 2 45 6 2.2 40 6 2.0
Fifty microliters of blood from a normal donor was incubated with 50 ml of patient plasma (IgA concentration from 4.0 to 7.1 mg/ml) for 1 hour at
4°C and cells were washed. Treated and untreated blood cells were stained at 4°C with F(ab9)2 fragments of anti-IgA antibodies coupled to phycoerythrin
(PE). Cells were analyzed by flow cytometry as described in Figure 1. Fluorescence intensity (FI) of control and IgAN cells were obtained in the peak
channel of each FACS profile. FI was calculated as described in Figure 1. N 5 number of patients.
a Significant differences between untreated and plasma-treated cells, Mann-Whitney test
b NS, no significant difference
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levels on monocytes (r 5 20.45, P , 0.003) and neutrophils (r 5
20.48, P , 0.002) from IgAN patients and controls (Fig. 4C).
As the decreased reactivity of anti-FcaR mAbs conflicted with
the increased FI values observed in previous studies [24, 34, 35],
we compared surface staining in direct (PE-labeled anti-FcaR
mAb) and indirect (anti-FcaR mAb cross linked by fluorochrome-
labeled secondary antibodies) fluorescence techniques in some of
the individuals studied above (10 IgAN patients and 10 controls).
We found a slight but sometimes statistically significant increase,
in FI values using the indirect technique (monocyte FI, 11.8 6 0.5
and 10.6 6 0.4; neutrophil FI, 7.5 6 0.6 and 6.2 6 0.5 for IgAN
patients and controls, P 5 0.17 and P , 0.05, respectively), as
previously described [24], and confirmed the significant fall in FI
values obtained above with PE-labeled anti-FcaR mAb on IgAN
Fig. 4. Immunofluorescence analysis of FcaR
on blood phagocytes from patients with IgAN
and other types of GN. Blood cells from
patients and controls (Co) were directly stained
with phycoerythrin (PE) labeled anti-FcaR
mAb A59 (0.05 mg/ml) as described in the
Methods section. Cells were analyzed by FACS
as described in Figure 1. (A) Representative
FACS profiles of neutrophils and monocytes
from a control and an IgAN patient. Overlayed
left histograms represent background
fluorescence with IgG1k irrelevant control
monoclonal antibodies (mAb). The fluorescence
intensity (peak channel) of A59 mAb staining
was 38.96 and 23.83 (patient) and 78.74 and
48.64 (control) for monocytes and neutrophils,
respectively. (B) Fluorescence intensity (FI)
values for controls and IgAN patients were
obtained in the peak channel of each FACS
profile and calculated as described in Figure 1.
Differences between controls and patients were
analyzed by Student’s t-test and the Mann-
Whitney U test. *P , 0.001; **P , 0.001. (C)
Linear regression analysis between serum IgA
and FcaR levels in IgAN patients (N 5 24; F)
and controls (N 5 18; E). In monocytes r 5 2
0.45, P , 0.003; in neutrophils, r 5 20.48; P ,
0.002.
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phagocytes (monocyte FI, 32.7 6 1.2 and 49.2 6 2.4; neutrophil
FI, 17.3 6 0.9 and 26.4 6 1.2 for IgAN patients and controls;
Mann Whitney U test, P , 0.01 and P , 0.05, respectively).
Cytoplasmic pool of FcaR molecules was also evaluated by IF
staining of permeabilized neutrophils and MNC from four IgAN
patients and four controls using an anti-FcaR mAb (A59). Figure
5 shows representative cytoplasmic staining of monocytes and
neutrophils from an IgAN patient and a control. Monocytes were
identified within MNC by double staining with an anti-CD14 mAb
(not shown). Monoclonal antibody A59 fluorescence intensity was
consistently decreased in monocytes from patients compared to
controls (Fig. 5B, arrow). In contrast, cytoplasmic staining of
patients’ neutrophils was slightly enhanced compared to controls
(Fig. 5B). Similar results were obtained with another anti-FcaR
mAb, A62 (not shown). Staining of both cell types with anti-
FcgRII mAb (clone IV.3) showed no differences between patients
and controls (Fig. 5C).
Biochemical nature of FcaR molecules on patient blood cells
To characterize the FcaR molecules on blood phagocytic cells
from IgAN patients, surface-iodinated FcaR protein from cells of
five IgAN patients were compared to controls in SDS-PAGE. In
Fig. 5. Analysis of cytoplasmic pool of FcaR in monocytes and neutrophils from an IgAN patient. Isolated mononuclear cells (MNC) and neutrophils
were cytospun, fixed and permeabilized in 95% ethanol/5% acetic acid at 220°C and stained with an irrelevant IgG1k (A), anti-FcaR A59 monoclonal
antibody (mAb) (B), or anti-FcgRII IV.3 mAb (C) plus FITC-coupled goat anti-mouse Ig Ab as the developing reagent. The arrow indicates the absence
of cytoplasmic staining on monocytes.
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a preliminary experiment no FcaR protein was immunoprecipi-
tated from IgAN monocytes; immunoprecipitation was therefore
performed on lysates subjected to only three FcgR pre-adsorp-
tions to avoid nonspecific loss of material. Figure 6 shows the
results of four experiments performed with cells from controls and
IgAN patients (S.L., J.O., P.M. and A.R.). Scan analysis revealed
a marked decrease in surface FcaR expression on IgAN mono-
cytes (278 6 9%, range 293% in P-1 to 252% in P-4) compared
to controls (Fig. 6A, lanes 2 vs. 4), whereas 40-kDa FcgRII
protein was detected in samples from both controls and patients
(lanes 5 vs. 6). An increase in FcaR Mr was observed in one IgAN
monocyte sample (patient A.R.) and in all IgAN neutrophil
samples compared to the respective control cells (Mr 60 to 85 kDa
and 55 to 75 kDa, respectively) in individual side-by-side SDS-
PAGE analysis for each patient and control pair (Fig. 6A, C-4 vs.
P-4, and Fig. 6B, lanes 10 vs. 8). Removal of N-linked carbohy-
drates by N-glycosidase F revealed the expected 32 kDa and 36
kDa bands in both patients and controls (data not shown). A slight
decrease in the intensity of the neutrophil FcaR band was
observed in patients compared to controls (215 6 7%, range
25% in P-4 to 236% in P-3). Similar results were obtained using
two different anti-FcaR mAbs (A62 and A77; not shown).
Alterations in FcaR mobility in side-by-side SDS-PAGE led us
to evaluate FcaR sialic acid content by lectin binding. SNA lectin
was used on immunoblots of FcaR immunoprecipitates from
neutrophils of four IgAN patients and four controls. Figure 7
shows decreased SNA binding to FcaR immunoprecipitates in
three patient samples (P-5, P-6 and P-7 lanes 4 vs. lane 2, arrows),
whereas no difference was observed in Con A binding (Fig. 7A,
lane 8 vs. lane 6). Similar results were obtained with FcaR
samples from patient P-1 (data not shown). FcaR proteins
appeared as bands with Mr values between 52 and 65 kDa as
determined by molecular weight markers on mini-SDS-PAGE.
Analysis of FcaR trancripts from mononuclear cells
To determine if decreased FcaR expression was due to defec-
tive messenger RNA levels, primers in the 59 and 39 regions of the
FcaR gene were used to amplify FcaR transcripts from MNC in
a PCR assay. As shown in Figure 8, no detectable differences in
the three previously described FcaR transcripts [23] were found
Fig. 6. Comparative analysis of surface FcaR
proteins on monocytes and neutrophils from
four IgAN patients by SDS-10% PAGE. Equal
numbers (2 3 107) of purified monocytes (A)
and neutrophils (B) from patients (P-1, S.L.;
P-2, J.O.; P-3, P.M.; P-4, A.R.) and controls
(C-1, R.M.; C-2, C.P.; C-3, A.L.; C-4, C.S.)
were surface-labeled with Na125I, and
membrane proteins were then solubilized in
0.5% NP-40 lysis buffer as described in the
Methods section. Cleared lysates were
incubated with an irrelevant mouse IgG1k
(lanes 1, 3, 7, 9), A59 anti-FcaR mAb (lanes 2,
4, 8, 10) or IV.3 anti-FcgRII mAb (lanes 5, 6)
plus goat anti-mouse Ig coupled to Sepharose
4B beads. Immunoprecipitation of C-4 and P-4
lysates was performed directly with IgG1- or
A59-coupled Sepharose beads. The 65- and 72-
kDa bands represent background, observed with
control IgG1 and A59 mAb, due to the small
number of lysate pre-adsorptions (to avoid loss
of material). Molecular weight markers are
indicated (kDa).
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between three patients and three controls in the linear phase (30
cycles) of the PCR assay. PCR products were hybridized with an
FcaR cDNA probe (not shown). Actin was used as a control for
RNA input. No mutation was found in the sequence of the
full-length transcript (a.1; 896 bp) cloned from PCR products
obtained from MNC of patient S.L. (two clones were sequenced
independently; data not shown).
In vitro evidence for FcaR down-regulation on monocytes by
IgA
To examine for the presence of circulating factors leading to
receptor modulation, we first analyzed FcaR expression before
and after incubating blood in absence of plasma for one hour at
37°C. In these conditions, FcaR was significantly up-regulated on
monocytes and neutrophils (Fig. 9A). This was also obtained
when adherent monocytes from either control or patient MNC
were cultured for five days in RPMI containing fetal calf serum
(FCS), but not with autologous human serum (AHS), indicating
the presence of circulating regulatory factors (Fig. 9 B, C). Since
IgA can induce increased IgA binding to U937 cells in a concen-
tration-dependent manner [21], we examined whether decreased
FcaR expression could be dependent on concentration and type
of the purified IgA. U937 or normal blood monocytes were
cultured with purified IgA in the presence of polymyxin B to
prevent the effects of contaminating lipopolysaccharides, which
have been described to up-regulate FcaR expression [36, 37]. As
shown in Figure 10A, increased concentrations of polymeric
myeloma IgA1k (up to 10 mg/ml) in the culture medium induced
increased IgA binding to U937 cells, as previously described [21],
but did not significantly modify FcaR expression, when cells were
cultured for 24 hours (Fig. 10B). The long-term effect of IgA on
FcaR expression was studied on normal blood monocytes rather
than U937 cells. Purified IgA from sera of six IgAN patients and
six normal individuals were added to culture of normal blood
monocytes for five days at 5 mg/ml. A significant increase in IgA
binding was observed using IgA from IgAN patients as compared
to those from controls (Fig. 10C). Interestingly, serum IgA from
IgAN patients induced a marked decrease in FcaR expression,
although without significant differences as compared to those
from controls (Fig. 10D). We next investigated the role of IgA
forms in the regulation of FcaR expression using polymeric and
monomeric fractions of a myeloma IgA1k that were separated/ by
gel chromatography. Polymeric IgA bound more to monocytes
after five days in culture at 5 mg/ml (Fig. 10E) and induced a
stronger down-regulation of FcaR than monomeric IgA1k (76%
vs. 47% decrease in FI, respectively; Fig. 10F). FcaR down-
regulation was also obtained following culture with myeloma
IgA1l and IgA2 (Fel) but not with human IgG at 5 mg/ml in three
experiments (data not shown).
Links between FcaR abnormalities on blood monocytes and
morphological lesions on renal biopsies
To determine if receptor occupation by IgA on blood cells
could be involved in glomerular inflammation, we first divided
patients in two groups according to the mean FI values of either
IgA or FcaR staining and compared biopsy findings. As shown in
Table 2, the percentages of patients with mesangial proliferation
and glomerular sclerosis were significantly higher in the group of
patients with a high level of IgA receptor occupation on mono-
cytes (FI . 3). No statistical difference in glomerular abnormal-
ities was seen between the two groups of patients defined by FcaR
expression on monocytes (mean FI # or . 34; data not shown).
No difference was seen on neutrophils.
Fig. 7. Evidence of impaired sialylation of FcaR in patient neutrophils.
Immunoprecipitates (IP) were obtained from neutrophil lysates of three
normal individuals (C-5, C-6 and C-7) and from three IgAN patients (A,
P-5, patient S.I.; B, P-6, patient A.G.; C, P-7, patient J.A.) using either a
control IgG1 mAb or an anti-FcaR mAb (A59) as described in Figure 6.
Immunoprecipitates were then divided into two aliquots (IgG1, lanes 1, 3,
5, 7; and A59, lanes 2, 4, 6, 8), separated on SDS-10% PAGE and
immunoblotted (IB) with biotinylated lectins: Sambucus nigra agglutinin
(SNA; lanes 1 to 4), which binds to the terminal sialic acid linked to
galactose; and Concanavalin A (Con A; lanes 5 to 8), which binds to
carbohydrates with terminal mannose or glucose residues. Lectin binding
was revealed by horseradish peroxidase-labeled streptavidin and then
developed using an enhanced chemiluminescence detection system. Mo-
lecular weight markers are indicated (kDa).
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DISCUSSION
We studied the expression of FcaR molecules to further
understand the increased occupation of FcaR by endogenous
IgA1 in patients with IgAN. Surface expression of FcaR was first
analyzed by flow cytometry. Diminished reactivity of anti-FcaR
mAb and decreased exogenous IgA1 binding to monocytes and
neutrophils were observed in blood samples from IgAN patients,
whereas these cells had normal levels of another myeloid marker,
CD32. Normal reactivity of anti-FcaR antibodies in other types of
GN, such as membranous GN and minimal change disease,
suggests a specific defect in FcaR expression in IgAN patients.
The decreased FcaR reactivity on blood cells of IgAN patients
reported here conflicts with earlier observations of increased
reactivity of anti-FcaR mAb [24, 34, 35]. However, these differ-
ences can be explained by the methodology used to study receptor
expression (direct vs. indirect IF). The increase in FI values
observed in IgAN [24, 34, 35] could be due to abnormal receptor
clustering following cross linking by the secondary antibody in the
IF assay. Indeed, in our study a direct comparison of the two
techniques on samples from the same individuals showed that
while the indirect technique (cross linking by a secondary anti-
body) yielded a slight increase in FI values in IgAN, as previously
described [24], the direct assay (fluorochrome-labeled anti-FcaR
mAb) showed a significant decrease in FI values, which correlated
with lower amounts of surface FcaR molecules in immunopre-
cipitation analysis (Fig. 6). Our biochemical studies revealed that
FcaR molecules were strongly diminished ex vivo on IgAN
monocytes (278 6 9%) and slightly diminished on neutrophils
(215 6 7%), as determined by scan analysis. One possible
explanation for the severe loss of FcaR expression on IgAN
monocytes but not neutrophils could be differences between the
two cell types in synthesis and/or intracellular trafficking of FcaR.
This is supported by cytoplasmic FcaR staining that was de-
creased in monocytes and slightly increased in neutrophils. It is
unlikely that the decreased receptor precipitability was an artifact
generated by external factors such as endogenous IgA occupation
of FcaR (which could lead to steric hindrance interfering with the
ability of lactoperoxidase to radio-iodinate receptor tyrosine
residues) for the following reasons: (i) decreased FcaR expression
was detected by two different methods (IF and immunoprecipi-
tation) using several anti-receptor mAbs (A59, A62 and A77)
recognizing epitopes located outside the IgA binding site; and (ii)
normal FcaR iodination was observed on monocytes from pa-
tients with ALC, a disease with even higher receptor occupation
by IgA (two- to threefold the levels found in IgAN) [26]. It is also
unlikely that IgA-IC bound to FcaR could interfere with the
accessibility of mAbs in recognizing epitopes on FcaR extracel-
lular domains, as decreased FcaR expression was also observed
on patient cells after an immunoprecipitation experiment using a
homemade polyclonal antibody anti-cytoplasmic region of FcaR
(data not shown).
Decreased receptor expression led us to evaluate FcaR tran-
scripts in MNC of IgAN patients. No quantitative differences in
transcripts were observed between patients and controls using a
semiquantitative RT-PCR assay. In addition, no mutation was
detected in the full-length transcript (a.1) of an IgAN patient
(with marked decrease in FcaR expression). These results rule
out genetic abnormalities in the coding region of the FcaR gene.
Moreover, the findings of slightly higher SDS-PAGE mobility of
remaining surface FcaR (Mr 60 to 85 vs. 55 to 75 kDa) and
decreased receptor binding to sialic-acid specific lectins in blots
suggest that FcaR sialylation might be altered at the post-
translational level. Impaired sialylation could explain altered
mobility of iodinated surface FcaR molecules on SDS-PAGE. It is
noteworthy that FcaR expression in IgAN strongly resembles that
in patients with HIV infection, with a similar marked decrease in
Fig. 8. Reverse transcription-polymerase chain
reaction (RT-PCR) analysis of FcaR
transcripts in mononuclear cells (MNC) from
IgA nephropathy (IgAN) patients. RT-PCR
amplification of the FcaR transcripts was
performed using total RNA isolated from 5 3
106 mononuclear cells from controls and IgA-N
patients as described in the Methods section.
(A) Determination of the linear phase of the
PCR assay, using samples from a control (C)
and an IgAN patient (P), where the number of
cycles is indicated at the top of the wells. (B)
Comparative analysis of FcaR transcripts in
three IgA-N patients and three controls after 30
PCR cycles. b-actin was used to verify RNA
quality. Co represents a PCR-negative control
in the absence of cDNA.
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monocyte FcaR expression and altered SDS-PAGE mobility of
neutrophil FcaR [25]. It has been demonstrated that HIV infec-
tion induces alterations in SDS-PAGE mobility and sialylation of
CD43 molecules [38]. Viral infection of the upper respiratory
tract, a common feature in IgAN patients [3], could lead to
alterations in FcaR sialylation. One of the factors that could be
involved in the genesis of altered FcaR sialylation on blood cells
is interferon-g, as it can induce FcaR expression on U937 cells
with altered mobility on SDS-PAGE [26]. It is noteworthy that
elevated levels of interferon-g are indeed found in plasma of
IgAN patients [39].
The fact that FcaR can be rapidly up-regulated in the absence
of serum and clearly down-regulated when monocytes were
cultured with autologous serum suggests a role of circulating
regulatory factors. These findings, together with the observation
of decreased FcaR expression in ALC and AIDS [25, 26], diseases
with increased levels of serum IgA and different ethiopathogen-
esis, led us to investigate the role of IgA in the regulation of FcaR
expression. Long-term cultures of normal monocytes with serum
IgA (at 5 mg/ml) induced a consistent decrease in FcaR expres-
sion. Specificity of such down-regulation was provided by the lack
of effect of human IgG. The absence of significant differences in
receptor down-regulation by IgA between patients and controls
indicates that the serum level of IgA itself plays a role in
regulation of receptor expression on monocytes. This is in agree-
ment with the strong FcaR expression observed on monocytes of
IgA-deficient patients [30; our unpublished observations]. More-
over, our experiments culturing monocytes with different forms of
purified myeloma IgA demonstrated that polymeric IgA bound
more to FcaR than monomeric IgA, confirming a previous
observation [30], and induced stronger down-regulation as com-
pared to monomeric IgA. These experiments point to a putative
role of serum IgA, especially for polymeric forms or IgA-IC, in
decreased FcaR expression observed on monocytes of IgAN
patients. As polymeric IgA and IgA-IC are commonly found in
serum of these patients [5, 17], it can be suggested that these
ligands could induce continual receptor aggregation resulting in
stronger down-regulation of FcaR.
It is generally accepted that FcR plays an important role in Ig
catabolism. For example, a balance between IgG protection and
degradation by FcgR determines the IgG serum level [40]. In
mice, deficiency in an IgG protection receptor (FcRn) results in a
short IgG half-life [40, 41], whereas impaired expression of
FcgRII isoforms (b2 and b3) in macrophages of nonobese diabetic
mice is linked to increased IgG1 and IgG2b serum levels [42].
More importantly, the latter defect (mutations in the FcgRII
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Fig. 9. Up-regulation of FcaR on cells cultured in absence of autologous
serum. (A) Blood cells were washed with sterile PBS containing 5% FCS
and incubated or not for 60 minutes at 37°C. Cells were then stained with
A59, as described. The stained cells were analyzed by flow cytometry and
results were expressed as FI index, as described in Figure 1. FcaR FI index
values were presented as the mean 6 SD obtained from six different
experiments. *P , 0.01, significantly different from control (independent
t test). (B and C) Mononuclear cells from a normal individual (B) and
from an IgAN patient (C) were cultured for five days in RPMI containing
30% fetal calf serum (FCS) or autologous human serum (AHS) as
indicated. Cells were stained with A59-PE, as described in Figure 4. The
thick solid line indicates MNC before culture and the dotted line the
background obtained with isotype matched control.
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Fig. 10. In vitro evidence for down-regulation of FcaR on normal blood monocytes following culture with serum IgA. (A and B) U937 cells (0.2 3
106/ml) were cultured for 24 hours in RPMI containing 20 mg/ml polymyxin B and 10% FCS alone or with twofold dilutions of myeloma IgA1k (10
mg/ml). Cells were washed and stained with F(ab9)2 fragments of anti-IgA Ab-coupled to phycoerythrin (PE; hatched columns) or A59 anti-FcaR
mAb-coupled to PE (solid columns), as indicated. Results are expressed in FI index as described (21). (C and D) Adherent blood mononuclear cells
(MNC) from normal individuals were cultured for five days in RPMI containing polymyxin B and 10% FCS in the presence or absence of IgA (5 mg/ml)
purified from sera of six normal individuals as controls (IgA-Co) or from six IgAN patients (IgAN), washed and stained as described above. Results were
presented as FI index and as mean 6 SEM. (E and F) Adherent cells from normal individuals were cultured for five days in RPMI containing polymyxin
B and 10% FCS (medium) in the presence or absence of 5 mg/ml of purified polymeric (pIgA) or monomeric (mIgA) myeloma IgA1k. Cells were
removed as described in Methods and stained with anti-IgA Ab-PE (E) or A59-PE (F). Overlayed left histograms represent background fluorescence
with a polyclonal Ab or an irrelevant mAb coupled to PE, for E and F, respectively. P , 0.05, Student’s t-test.
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promoter region) is corrected in congenic mice carrying a normal
promoter region from C57BL/6J, and this normalizes serum IgG
levels. Once aggregated, FcaR mediates the degradation of IgA
complexes through an endolysosomal pathway [26], and thus
might play a role in IgA catabolism. Here, we show that decreased
FcaR expression on IgAN myeloid cells is associated with in-
creased serum IgA levels and with FcaR occupation by IgA1.
There is compelling evidence that IgA itself plays a role in FcaR
occupation. The first putative mechanism could be mediated
simply by the increase in serum IgA levels, as a consequence of
enhanced IgA synthesis by B lymphocytes observed in IgAN [18].
Indeed, increasing IgA concentrations in the culture medium of
U937 cells resulted in a gradual increase in IgA binding to FcaR,
without increasing receptor expression. This can be explained by
up-regulation of FcaR (CD89) affinity for the IgA ligand and/or
induction of a second uncharacterized IgA receptor. Secondly,
qualitative alterations of IgA may also play a role in abnormal
receptor occupation. Culture of U937 cells (not shown) or normal
blood monocytes with patient IgA induced a ;twofold increase in
IgA binding compared to control IgA at the same concentration
(5 mg/ml). This is in agreement with a report [43] of increased IgA
binding to the U937 and THP-1 cell lines after one hour of
incubation with patients’ IgA at 37°C. Interestingly, desialylation
of IgA1 myeloma increased binding to U937 receptors [13].
Abnormally glycosylated IgA may thus play a direct role in the
increased IgA binding to FcaR in IgAN. It is noteworthy that
FcaR binds to an unusual binding site of IgA, the intradomain
boundary between Ca2 and Ca3, and that glycosylation of the
Ca2 domain may be essential for the FcaR-IgA interaction [44].
However, the increase in IgA levels and altered IgA structure
cannot alone explain increased receptor occupation in IgAN, as
preincubation of normal blood cells with patients’ plasma at 4°C
failed to reconstitute the high levels of IgA bound to patients’ cells
(Table 1). One possible cause of the increased IgA1 bound to cell
surface receptors is the impaired sialylation of FcaR, which could
modify receptor-ligand affinity. This is supported by the fact that
removal of sialic acid by sialidase treatment of U937 cells results
in a fivefold increase in IgA binding to FcaR [21]. Increased
affinity for IgA of FcaR could thus contribute to enhancement of
receptor occupation by IgA despite the low receptor numbers.
An alternative mechanism involves recycling of FcaR-IgA
complexes. Intracellular IgA was clearly detected in monocytes of
IgAN patients by IF with an anti-IgA mAb (Fig. 3), as also
described by others using an ELISA [45]. This suggests that
surface-bound IgA can be internalized but not completely de-
graded. Altered FcaR expression, associated with surface-bound
IgA1, intracellular IgA and delayed kinetics of endocytosis [24]
point to altered recycling of FcaR-IgA complexes towards the cell
surface in blood myeloid cells in IgAN. This has also been found
in ALC [26]. Continuous FcaR occupation by IgA and recycling
of receptor-bound IgA may increase levels of serum IgA and
IgA-IC by protecting them from degradation through the endoly-
sosomal pathway, and might also contribute to the defective
clearance of IgA-IC observed in IgAN patients [19]. This mech-
anism might also contribute to increasing serum concentrations of
abnormally glycosylated IgA [11–15] and might thereby play an
indirect role in the formation of mesangial IgA deposit.
Finally, our observations indicate a linkage between FcaR
occupation by IgA on monocytes and mesangial proliferation or
glomerular sclerosis, which suggests that IgA-bound cells may play
a direct pathogenic role in the mesangium. Cross linking in situ of
FcaR-bound IgA by antigens, immune complexes and/or mesan-
gial IgA receptor(s) might damage the mesangium through the
release of inflammatory mediators. Indeed, tumor necrosis fac-
tor-a (TNF-a) and interleukin-6 (IL-6) are produced following in
vitro aggregation of FcaR on normal monocytes [46]. TNF-a
could play a direct role in mesangial damage by inducing apopto-
sis [47], while IL-6 can promote mesangial cell proliferation [48,
49]. Taken together with the observations that intraglomerular
macrophages are very common in IgAN and that their numbers
correlate with disease outcome [50], and with preliminary data
revealing FcaR1 intraglomerular macrophages (not shown), our
results open the possibility for a direct role of the abnormal
interaction between FcaR and IgA in the pathogenesis of the
disease.
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APPENDIX
Abbreviations used in this article are: ALC, alcoholic liver cirrhosis;
FcR, Fc receptors; FI, fluorescence intensity; HIV, human immunodefi-
ciency virus; IgA, immunoglobulin A; IgAN, IgA nephropathy; mAb,
monoclonal antibody; MNC, mononuclear cells.
Table 2. Links between FcaR occupation by IgA and morphological findings on renal biopsies of IgA nephropathy (IgAN) patients
Cell
type
IgAN
patient
Na
IgA
FIb
Mesangial
proliferation
N (%)
Glomerular
sclerosis
N (%)
Crescents
N (%)
Tubulointerstitial
lesions
N (%)
Arteriolar
damage
N (%)
MN 8 #3 2 (25) 2 (25) 3 (37) 6 (75) 6 (75)7 .3 7 (100) 7 (100) 3 (43) 7 (100) 6 (86)
p , 0.02 p , 0.02 NS NS NS
PMN 10 #2 5 (50) 5 (50) 5 (50) 9 (90) 8 (80)5 .2 4 (80) 4 (80) 1 (20) 4 (80) 4 (80)
NS NS NS NS NS
Abbreviations are: MN, monocytes; PMN, neutrophils. Statistical differences between percentages were identified using Yates’ x2 test; NS, no
significant difference.
a N, number of patients studied from those presented in Fig. 1
b FI represents two groups of fluorescence intensity values (peak channel) established on mean values for patients shown in Figure 1
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